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Our assignment is to cover the literature on urate
excretion as studied by microtechniques, the re-
lated studies on drugs, and sufficient other literature
to put the foregoing in context. In addition, we have
been asked to comment on certain technical prob-
lems attending studies of urate transport in individ-
ual nephrons. Space will not permit systematic con-
sideration of the various drugs known to alter the
renal disposition of urate in one or more species.
Instead, we will concentrate on the physiologic fac-
tors of urate excretion that determine the direction
and extent of drug action. Much of the literature on
individual drugs has been summarized in recent re-
views [1—4].
A large fraction of the interesting observations on
urate excretion have been made in studies on hu-
mans. Some of the interpretations of these phenom-
ena were based on observations made in other ani-
mals. For example, observe the use of comparative
physiology in the Gutman and Yü exposition of the
three-component mechanism for urate excretion
[5]. Later, attempts were made to verify the hypoth-
eses developed for the human kidney by studies in
animals with a variety of techniques including mi-
cropuncture, in vivo microperfusion, in vitro micro-
perfusion, tubular microinjection, and capillary mi-
croperfusion. These studies and others using more
conventional techniques are producing a pattern of
great complexity in the comparative physiology of
urate excretion and, to our surprise, of organic ani-
on transport in general. This complexity may be
viewed either as offering a variety of opportunities
for finding particular models of the phenomena ob-
served in humans or as a variety of traps leading to
spurious interpretations of human physiology. Both
views have merit.
Urate excretion in humans: Survey. To provide a
framework, we begin with a succinct description of
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the current understanding of urate excretion in nor-
mal humans. Urate is almost completely ultrafilter-
able from human plasma [6]. It is largely reab-
sorbed; fractional excretion is usually less than 0.10
[7]. Reabsorption can be inhibited by uricosuric
drugs such as probenecid and sulfinpyrazone [4].
Most uricosuric substances are organic anions, but
a few organic bases are uricosuric [1]. It is not
known if the bases themselves or acidic metabolites
of the bases are the true uricosuric agents. There is
good but indirect evidence that the magnitude of
uricosuric response depends on the concentration
of drug in tubular fluid [8-12]. The site of urate reab-
sorption (and therefore of uricosuric action) is not
known, but the results from laboratory animals sug-
gest that the major site exists somewhere in the
proximal tubule (see below). There is also secretion
of urate that is normally masked by the more exten-
sive reabsorption [7]. Net secretion of urate as a
spontaneous phenomenon has been observed in a
few individuals [13—16]; it can be elicited in other
subjects with special procedures [17]. The secretory
component can be inhibited, most notably by pyra-
zinamide (actually by its metabolite, pyrazinoic
acid) [7, 18]. In the normal individual with net reab-
sorption of urate, pyrazinoate causes a sharp de-
crease in urate excretion [7]. The site(s) of urate se-
cretion is not known, but it is probably somewhere
in the proximal tubule [19]. Reabsorption may be an
active transport process; with water diuresis and in-
hibition of secretion, the concentration of urate in
urine may be as low as one tenth of the concentra-
tion in plasma [20]. Secretion is probably an active
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transport process, for net secretion has been ob-
served [13—17]. The secretory component for urate
is distinct from the mechanism that secretes para-
aminohippurate (PAH) [21]. Some drugs (for ex-
ample, salicylate) that are uricosuric at high doses,
cause urate retention at lower doses [12]. It is
thought that such drugs are more potent inhibitors
of urate secretion than they are of urate reabsorp-
tion. Certain pairs of uricosuric drugs when admin-
istered together, both at normally uricosuric doses,
may elicit no response or a response inferior to that
obtained with either drug alone [22, 23]. The mutual
inhibition of action is thought to stem from two phe-
nomena operating simultaneously: (1) drug A inhib-
its the secretion of drug B, limiting its access to the
site of uricosuric action; (2) drug B inhibits the se-
cretion of urate, thus compensating for the un-
cosuric tendency of drug A [8, 24]. The renal clear-
ance of urate is enhanced by extracellular volume
expansion [25-27] and diminished by extracellular
volume contraction [20, 28]. The influences of these
changes in extracellular volume are thought to be
exerted in the proximal tubule. Water diuresis itself
has minimal influence on urate clearance, suggest-
ing that the terminal nephron is virtually imper-
meable to urate [29].
Microanalytical methods. The foregoing catalog
of phenomena and interpretations provides a rich
background for detailed studies with micro-
techniques. Before recounting the results with these
methods, we will consider the problem of estimat-
ing urate in microsamples and in the plasma of ani-
mals with low endogenous concentrations of urate.
There is some disparity in the literature on urate
excretion, which undoubtedly arises from dif-
ferences in experimental settings (for example, state
of hydration) and possibly from differences among
strains of the same species [30]. The role of these
factors in producing the disparaties cannot be quan-
tified at the present time. Other discrepancies seem
to stem from the analytical methods for urate deter-
mination. The earliest studies used in situ micro-
perfusion and tubular microinjection techniques
with 2-'4C-urate [31, 32]. There is good reason to
think that the radioactivity in collected perfusate or
urine in these studies was indeed contained in urate
[33]. The clearance data from one study [34] are
clearly in error; the rapid conversion of circulating
urate to allantoin was not considered. Another ap-
proach has been to infuse 2-'4C-urate and then sepa-
rate urate from its metabolites in the samples of
plasma, urine, and tubular fluid [35]. This method is
theoretically sound, and its developers provided ex-
tensive evidence for its validity [36]. The biologic
results with this technique, however, do not agree
with results obtained with three different, apparent-
ly valid techniques (see section on the rat). This dis-
crepancy has not yet been explained. A third radio-
chemical approach is the use of 6-14C-urate [37, 38].
The isotope in the sixth position is discharged as
14C02 when urate is converted to allantoin. If pre-
cautions are taken to eliminate carbon dioxide from
the biologic samples, the method should theoreti-
cally give valid results. The clearance and micro-
puncture results with this method are similar to
those obtained with some of the chemical methods
(see below).
A microadaptation of the Folin method has been
applied to micropuncture samples [39]. This method
overestimates the concentration of urate in urine
and presumably also in tubular fluid [40]. This is the
only method that indicates net secretion of urate
throughout the proximal tubules of rats [39]. A dif-
ferent modffication of the Folin method gives clear-
ance values in rats that are in the same range but not
identical to those obtained with 6-14C-urate [37].
The spectrophotometric enzymic method (change
in absorbance attending the destruction of urate by
unicase) is generally considered the most specific of
the chemical methods [41]. It is, unfortunately, not
sufficiently sensitive for micropuncture samples.
Moreover, great care must be exercised in applying
the method to plasma from rats and other animals in
which the concentration of urate is very low, 10 g/
ml or less. The unease-oxygen-sensing method
gives values for urate in rat plasma that seem to be
erroneously high [38]. A micromodification of the
Bloch and Lata fluorimetric method has been ap-
plied to tubular samples from various species [42—
46]. It is sufficiently sensitive and fairly specific.
There are two major drawbacks: first, the method is
tedious; second, certain constituents of the diet in-
terfere, and the animals must be fasted [45].
Recently, the method of Pachla and Kissinger
[47], high performance liquid chromatography with
electrochemical detection, has been applied in mi-
cropuncture experiments [48]. This method is spe-
cific for urate and is the most convenient, sensitive,
and precise of the existing chemical methods.
Comparative physiology: (1) General consid-
erations. Table 1 lists the species in which urate
transport has been studied by one or more of the
microtechniques. The table is at least as useful for
indicating areas of incomplete information as for
cataloging existing facts. Indeed, some of the infor-
mation in the table is quite "soft." The table em-
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Table 1. Summary of results on urate and PAH transport by various animals studied with the aid of microtechniques a
Urate
reabsorption
Urate
secretion
PAH
secretion Urate secretion
inhibited by
PAH and urate
secreted by same
Species Nettransport Pconv Prect Pconv Prect Pconv Prect pyrazinoate mechanism
Monkey(Cebus) Reabs. +++ + ++ ? +++ +++ Yes No
Non-Dalmatiandog Reabs. ++ ++ ? Yes ?
Dalmatian Either Yes ?
Rabbit Either + + ? ? + + + + + + No Probable
Rat Reabs. ++ + ++ ++ ++ Yes No
Pig Secr. + + + + + + + + + + No Probable
Snake(Thamnophis) Secr. ++ ++ ++ ++ No
a Abbreviations are defined: P cony, pars convoluta; P rect, pars recta. The information in this table is from the following sources:
Cebus [45, 46, 49, 50]; non-Dalmatian dog [18, 44, 51, 52]; Dalmatian coach hound [44, 53, 54]; rabbit [43, 55—58]; rat [38, 40, 42, 59—64];
pig [65]; snake [66-69]. Additional information comes from as yet unpublished studies: Roch-Ramel et al (free-flow micropuncture study
of urate excretion in rats using the high performance chromatography method); Roch-Ramel, Simmonds, and Cameron (free-flow micro-
puncture study of urate and PAH excretion in the pig); Schäli and Roch-Ramel (accumulation of PAH by isolated tubular segments from
rabbit, pig, and Cebus monkey).
phasizes information on the proximal tubule, which
seems to be the main site of urate transport in all
species. Information on other segments will be
mentioned later. For present purposes, the proxi-
mal tubule is divided into only two parts, the con-
voluted portion and the pars recta (in the snake, the
distal portion of the proximal tubule is assumed to
be analagous to the mammalian pars recta). It is ap-
preciated that in some species at least, a morpho-
logically and functionally sound division of the
proximal tubule would require three parts, S1, S2,
and S3 [57]. The segment S2 in the rabbit contains
most of the secretory activity for PAH. Unfortu-
nately, most of the information on urate is not suffi-
ciently refined for application of the more sophisti-
cated morphologic classification.
Incomplete as it is, Table 1 reveals several impor-
tant facts. (1) The animals studied exhibit either net
secretion or reabsorption of urate; in some in-
stances the same species can exhibit net secretion
or net reabsorption depending on experimental con-
ditions and perhaps on the individual specimen. (2)
There is evidence for bidirectional transport in all
the species listed in the table. (3) The anatomical
distribution of urate secretory activity is not the
same in all species. (4) The anatomical distribution
of PAH secretory activity is not the same in all spe-
cies. (5) The anatomical distribution of urate secre-
tory activity does not always correspond to that for
PAH. (6) Pyrazinoate is a powerful inhibitor of
urate secretion in some species but not in others.
The last three factors taken together with infor-
mation to be considered below suggest that urate
secretion is not mediated by strictly homologous
mechanisms in the various species. In some in-
stances, it is quite clear that urate and PAH are Se-
creted by separate mechanisms; in others, the cur-
rent evidence is consistent with the idea that both
substances are secreted by the same mechanism.
We will pursue these questions further when con-
sidering the individual species.
Urate is almost entirely ultrafilterable from the
plasma of the warm blooded animals listed in Table
1 (see Roch-Ramel and Peters [3] for review). A di-
rect determination of the ultrafilterability of urate in
vivo has been made in the Munich-Wistar rat [40].
The ratio of urate concentrations, glomerular fluid!
plasma, was 0.99 0.025. The expected ratio, as-
suming complete ultrafilterabiity and taking into
account the protein content of plasma and the Don-
nan factor, is 1.08 to 1.10. Thus, at most, some 10%
of urate is bound to macromolecules in plasma. This
result has been confirmed by the electrochemical
method for determining urate (Roch-Ramel et al,
unpublished). There is virtually no protein binding
of urate in snakes [70].
(2) Rabbit. The concentration of endogenous
urate in plasma is very low, approximately 3 g/ml
[71]. There are two reports stating that net reab-
sorption of urate occurs when concentrations in
plasma are low and that net secretion occurs when
concentrations are high [72, 73]. Beechwood,
Berndt, and Mudge also reported net reabsorption
in some experiments and net secretion in others,
but they did not observe a dependence on plasma
concentration [58].
There is only one report of a free-flow micro-
puncture study on urate [43]. The experiments were
conducted with artificially elevated concentrations
of urate in plasma, 35 tg/ml; CurateIGFR was 1.6.
Despite this overall net secretion of urate, samples
from proximal convoluted tubules indicated net
668 Roch-Ramel and Weiner
reabsorption; TF/Purate/TF/Pinuiin averaged 0.80. In
isolated, perfused, proximal convoluted tubules
with urate added to the bath but not the perfusate,
there was some entry of urate into the luminal fluid,
but the concentration in the lumen did not reach the
concentration in the bath [74]. In contrast, the pars
recta (probably S2) secreted urate rapidly enough to
have the luminal concentration exceed the concen-
tration in the bath [74]. Experiments on the accu-
mulation of urate in nonperfused tubular fragments
gave confirmatory results [75]. These observations
suggest that net secretion of urate, when it occurs in
the rabbit, is largely a function of the pars recta.
The similarity of the distributions of secretory ac-
tivity for PAH and urate suggests that both sub-
stances are secreted by the same mechanism. Møl-
ler and Sheikh [55] have provided a succinct review
of the physiologic and pharmacologic evidence sup-
porting this view. In brief, urate and PAH appear to
inhibit the transport of one another in a competitive
manner, and many known inhibitors of PAH secre-
tion also inhibit urate secretion (see also Kippen et
al [76]). Although not all authors agree with this
proposition [77], it seems to us that the evidence
now available favors the view that both PAH and
urate are secreted by a common mechanism in the
rabbit.
It may be relevant that pyrazinoate does not di-
minish urate clearance in the rabbit [58]. This sub-
stance is a strong inhibitor of the secretory flux for
urate in some other species and a weak inhibitor of
PAH secretion [18].
(3) Pig. There are three studies on the renal trans-
port of urate in the pig; only one [65] is published at
this time. The results of the other studies will be
included in this summary because of their per-
tinence (the sources are given in the legend to Table
1). The concentration of endogenous urate in
plasma is about 3 gIml. Urate clearance exceeds
GFR by a factor of 1.6 to 3.3 at all levels of Purate up
to 80 gIml. Urate secretion is inhibited by proben-
ecid and PAH, but not by pyrazinamide or pyrazi-
noate. Urate and PAH secretion are evident
throughout the accessible proximal convoluted tu-
bule. With neither substance is it necessary to as-
sign an important secretory role to the pars recta;
that is, fractional delivery to micropuncture sites in
the proximal tubule is at least as great as fractional
excretion. When fragments of tubules are incubated
in vitro, there is considerably more accumulation of
urate or PAH in convoluted tubules than there is in
pars recta. Urate inhibits PAH accumulation and
vice versa; probenecid inhibits the accumulation of
both substances; pyrazinoate does neither. In vivo,
inhibition of urate secretion by high concentrations
of PAH reveals modest net reabsorption in proxi-
mal tubules and for the kidney as a whole.
Thus, the pig differs from the rabbit in one impor-
tant respect: the major secretory activity for both
PAH and urate occurs earlier in the pig nephron
than it does in the rabbit nephron. On the other
hand, it seems that in both species, PAH and urate
are secreted by a common mechanism. Within each
of the species, the distributions of secretory activi-
ties for PAH and urate are similar: both transport
mechanisms are insensitive to pyrazinoate and
there is mutual inhibition of transport between the
two substances.
(4) Snake. Snakes secrete both urate and PAH.
PAH secretion is largely confined to the late proxi-
mal tubule, whereas urate secretion is uniform
throughout the tubule [69]. PAH does not inhibit
urate secretion in vivo nor does it block urate accu-
mulation by kidney slices. Urate does not inhibit
PAH secretion by isolated perfused tubules [69].
Thus, on the basis of morphologic distribution of
secretory activity and tests for mutual inhibition of
transport [66], one can state that the two substances
are primarily secreted by separate mechanisms.
Probenecid depresses the secretion of both PAH
and urate [66] and thus seems to have affinity for
both transport mechanisms.
In addition to the secretory movement for urate,
there is an appreciable reabsorptive flux [67]. This
flux is easily demonstrated in experiments with iso-
lated perfused tubules in which urate is added to the
perfusate. The reabsorptive process is responsible
for the strong influence of luminal flow rate on net
secretion; the latter increases with increasing flow.
Dantzler [69] attributes reabsorption to passive ef-
flux of urate from the lumen, possibly via the inter-
cellular pathway. Other interpretations are possible
[78]. There have been no direct tests of the actions
of potential inhibitors on the efflux of urate from the
tubular lumen.
As is true for PAH in the pars recta of rabbit [56],
the concentration steps for both PAH and urate ex-
ist in the peritubular membrane; efflux from the
cells to the lumen is "downhill" [69]. The latter
transport step, however, seems to be specifically
mediated in the case of PAH, but not in the case of
urate [79]. Thus, both steps in the transepithelial se-
cretion of PAH and urate differ markedly, the one in
its distribution along the tubule and the other in
terms of specific mediation.
The evidence for the separateness of the secre-
tory mechanisms for PAH and urate in the snake is
more complete than it is in any other animal. The
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corresponding evidence in man [21] and the chim-
panzee [24], although based entirely on data from
clearance experiments, is quite strong. The evi-
dence in the animals to be considered subsequently
is much more equivocal. The uncertainties stem
from several factors. First, the distribution of PAH
secretory activities in some of these animals is not
known. Micropuncture studies on PAH secretion
have been done in the rat, but the results are not
uniform (see below). Second, the evidence for the
separateness of the urate and PAH secretory mech-
anisms comes largely from experiments in which
pyrazinoate was shown to inhibit urate excretion.
The impression is that pyrazinoate is a more potent
inhibitor of urate secretion than is PAH and is itself
a weak inhibitor of PAll secretion. Unfortunately,
complete dose-response relationships are not avail-
able. In each of the remaining species, PAH, albeit
with massive doses, has been shown to diminish
urate clearance. Some of the latter observations
may be complicated by an analytical artifact attend-
ing the estimation of urate in the presence of very
high concentrations of PAH (see Footnote 1 in Ref.
51). In view of these factors, the assignments of
urate transport to the PAH mechanism or another
mechanism in these species must be regarded as
tentative. (A general discussion of the difficulty in
distinguishing between single and multiple transport
mechanisms is given on p. 589 of Ref. 71.)
(5) Non-Da/matian dog. The concentration of
endogenous urate in plasma is about 3 j.g!ml [71].
Most studies have been conducted with artificially
elevated concentrations of plasma urate. There is
only one micropuncture study [44]. In this study,
Purate was artificially elevated to 28 pgIml, and frac-
tional excretion of urate was 0.49. There were no
differences in the fractional deliveries of urate to
late proximal tubules, distal tubules, and pelvic
urine. Thus, under the conditions of these experi-
ments (mild volume expansion), all net movement
of urate occurred before the end of the accessible
proximal tubules. Administration of pyrazinoate to
yield plasma concentrations averaging 125 j.g/ml re-
sulted in a statistically significant decrease in frac-
tional delivery to proximal sites, but there was no
influence on fractional delivery to distal tubules or
pelvic urine. Thus, on the basis of very few data,
there seems to be some compensation for the proxi-
mal effect of pyrazinoate by a more distal segment,
perhaps the pars recta.
Much more substantial evidence for a secretory
flux of urate somewhere in the proximal tubule and
its inhibition by pyrazinoate comes from studies
with the modified stop-flow technique [51, 52]. Con-
centrations of pyrazinoate of 30 j.g/ml or less cause
substantial inhibition of secretion. The same tech-
nique, however, reveals inhibition of urate secre-
tion by PAH [51, 52]. Only high doses of PAH were
studied; in one of the studies, PPAH was 350 g!ml
[51]. Thus, in the mongrel dog, the present evidence
does not allow one to distinguish between three
possibilities: (1) urate may be secreted by the PAH
mechanism; (2) urate may be secreted by an inde-
pendent mechanism which can be inhibited non-
specifically by very high concentrations of PAH; (3)
both types of mechanisms may exist.
(6) Dalmatian coach hound. The concentration of
endogenous urate is about 7 g/ml [71]. At this level
of urate, its renal clearance is equal to or less than
the filtration rate [53]. At higher concentrations of
urate in plasma, net secretion occurs [44, 53]. The
only micropuncture data come from experiments
performed with Purate at 24 sg/m1; Curate/GFR aver-
aged 1.42 [44]. The fraction of filtered urate found in
proximal samples was very variable (0.25 to 1.25);
the mean value was 0.96. It may be that there is
little or no net movement of urate in the convoluted
tubule. The large scatter of the data suggests, how-
ever, that some convoluted tubules may be demon-
strating net secretion; others, net reabsorption. The
mean fractional delivery of urate to distal tubules
was 1.37, a figure indistinguishable from fractional
excretion. Thus, it appears that most of urate secre-
tion occurs beyond the accessible proximal tubule,
a situation analogous to that in the rabbit. Pyrazi-
noate, 130 g/ml in plasma, caused a significant fall
in fractional delivery to proximal samples, and an
additional fall in samples from the distal tubule to a
value not different from mean fractional excretion,
which was 0.98. In some experiments pyrazinoate
converted net secretion of urate to net reabsorp-
tion. These results indicate inhibition by pyrazi-
noate of urate secretion in both the proximal con-
voluted tubule and pars recta. In a single experi-
ment, PAH inhibited urate secretion (PPAH, 300 ,g/
ml) [53]. Thus, as in the non-Dalmatian dog, there is
insufficient evidence to determine whether or not
urate and PAH are secreted by a common mecha-
nism.
(7) Cebus monkeys. The concentration of urate
in plasma usually falls in the range of 15 to 40 gJml
[49]. The enzyme uricase exists in the tissues of
Cebus [80]; the relatively high values of Purate are
the result, in part, of a high rate of synthesis [81].
Normal fractional excretion of urate is about 0.1
[49]. Most net urate reabsorption occurs in the
proximal convoluted tubule accessible to micro-
puncture [45]. Urate delivery to the "late" proxi-
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ma! tubule is about 25% of the filtered load. In non-
diuretic animals, fractional delivery to the distal tu-
bules is about 0.09 [48]. The reabsorption of urate
between the late proximal and distal tubules may
occur in the pars recta, but this is not proven. In
three studies, pelvic urine contained a smaller frac-
tion of filtered urate than did distal tubular samples
[45, 46, 48]. It is not known if this phenomenon re-
sults from a minor reabsorption of urate in the col-
lecting system or from differences between superfi-
cial and deep nephrons. The uricosuric action of a
probenecid analog, 2-nitroprobenecid, takes place
largely in the proximal convoluted tubule [45].
There is a secretory flux for urate that has been
identified in modified stop-flow experiments [50]
and in precession experiments in which droplets
containing labeled urate and inulin were placed on
the kidney surface [46]. This flux can be inhibited
by pyrazinoate. In clearance experiments, pyrazi-
noate reduces urate clearance in normal conditions
[46, 49, 82], when clearance has been previously
elevated with a uricosuric drug [46] and, most strik-
ingly, when clearance is enhanced by elevation of
Purate [49]. The major site of action of pyrazinoate
(and thus the site of the secretory flux) is the proxi-
mal convoluted tubule [46]. The combined action of
urate secretion and reabsorption in Cehus is such
that the concentration of urate in proximal fluid is
less than it is in plasma; reabsorption transport is
"uphill" [45]. Net secretion of urate has not been
observed in Cebus; it has been observed in humans
(see above) and chimpanzees [83].
The evidence that urate and PAH are secreted by
different mechanisms in Cebus is very indirect.
When urate clearance is increased by constant in-
fusion of a probenecid analog (2-nitroprobenecid),
subsequent challenge with hippurate results in a
diminution of uricosuria, and the diminution can be
Table 2. Data on endogenous plasma urate concentration (Purate)
and fractional excretion of urate in rats from several studiesa
Purute
p.gImI
Fractional
excretion
Analytical
technique Ref.
— 0.29 0.09 6-'4C-urate [37]
— 0.55 0.02 6-'4C-urate [38]
15.0 1.7 0.38 0.05 UV-uricase [39]
7.5 0.9 0.33 0.06 UV-uricase [60]
4.0 0.06 0.41 0.08 UV-uricase [84]
6.3 0.5 0.32 0.02 Fluonmetric [42]
6.5 0.5 0.34 0.02 HPLC-EC (Roch-Rameletal,
unpublished)
a Abbreviations are defined: UV, ultraviolet; HPLC-EC, high-
performance liquid chromatography with electrochemical detec-
tion.
attributed to a decrease in 2-nitroprobenecid excre-
tion; that is, its access to the tubular lumen is dimin-
ished [24]. In contrast, pyrazinoate can reduce the
uricosuric response to 2-nitroprobenecid without al-
tering its secretion; that is, it seems to be exerting a
selective effect on urate secretion [24]. It is empha-
sized, however, that PAH at high levels has been
reported to diminish urate excretion [50, 79]. Thus,
the situation in Cebus is not entirely clear, but the
evidence favors the idea that urate and PAH are se-
creted by separate mechanisms.
(8) Rat. There are very wide ranges of values for
endogenous Purate (4 to 15.3 gIml) and fractional
excretion of urate (0.12 to 0.90) in the literature on
rats (summarized in Ref. 3). Table 2 lists mean data
from studies in which blood was taken through in-
travascular catheters' and in which the analytical
method was the ultraviolet-unease method, the
fluorimetric method, the high-performance liquid
chromatographic method, or the 6-'4C-urate tracer
technique. With this selection of studies, the values
for Purate fall between 4 and 7.5 tg'ml with one ex-
ception. The results on fractional excretion of urate
are fairly congruent; the mean of these results is
0.37, with a range of 0.29 to 0.55.
Three of the foregoing studies included data from
free-flow micropuncture; these are summarized in
Table 3. Although there is considerable variation
among the data, several important factors are com-
mon to the three studies. First, there is appreciable
net reabsorption of urate by the time tubular fluid
reaches "early" proximal puncture sites. Second,
net reabsorption continues throughout the acces-
sible proximal tubule. Third, there appears to be
some net reabsorption of urate between the late
proximal tubule and the renal pelvis. Fourth, most
of the overall net reabsorption of urate occurs by
the end of the proximal convolutions.
A secretory flux for urate has been identified in
precession experiments [60, 85, 86]. This secretory
flux occurs, at least in part, in the proximal con-
voluted tubule, that is, the site at which most of net
reabsorption occurs [40].
There have been several in situ microperfusion
studies of urate reabsorption in the proximal tubule
[31, 40, 87, 88, 89]. With the exception of one study
[87], the results have been quite consistent. At per-
fusion rates of 20 p11mm, some 11 to 18% of per-
fused, radioactive urate is reabsorbed per millime-
I Techniques which result in some hemolysis yield spuriously
high values for Purate [40].
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Fig. 1. Fractional delivery of urale to early and late proximal
tubule and fractional excretion of urate at various concentra-
tions of plasma urate (P,te). The data are from the paper by
deRougemont et a! [42].
ter of tubule length. Three groups of investigators
agree that this fractional reabsorption is independ-
ent of urate concentration over a very wide range of
concentrations; that is, the process appears to fol-
low first-order kinetics [40, 87, 88].
The foregoing results seem to be inconsistent
with results of free-flow micropuncture experi-
ments. Figure 1 is constructed from data in the pa-
per by deRougemont et al [42]. It is quite clear that
fractional deliveries of urate to the early and late
proximal tubules and fractional excretion of urate
increase as Purate increases. One interpretation of
these results is that reabsorption is saturated as
Purate increases. This interpretation is at odds with
the evidence for first order reabsorption cited above.
A second possibility is that the secretory process for
urate follows kinetics of a higher order. The one
quantitative study of urate secretion suggests, how-
ever, that, over the range of concentrations studied,
secretion is a linear function of plasma urate con-
centration [40]. In the latter study, proximal tubules
were perfused in situ with urate-free solutions, and
urate entry into the perfusate was estimated with
the fluorimetric method. A third possibility is that
there is an endogenous inhibitor of urate secretion,
the effect of which is overcome as Purate increases.
The presence of such a presumed inhibitor would
not be apparent when the capillaries are perfused
with an artificial solution. If the latter speculation
should prove to be correct, one might expect that at
low (endogenous) concentrations of Purate in plasma
urate secretion would make only a small contribu-
tion to urate excretion in the rat. Other problems
related to the quantitative relationships between se-
cretion and reabsorption of urate in the rat are dis-
cussed elsewhere [3, 40, 78].
PAH is secreted by the proximal convoluted tu-
bule and the pars recta. The results of four studies
are summarized in Fig. 2. In two of the studies (A
and B), it seems that the convoluted tubules are not
inferior to the pars recta in terms of PAH secretion;
that is, fractional delivery to the late proximal tu-
bule is at least half the value of fractional excretion.
In two other studies (C and D), it appears that seg-
ments of the tubules beyond the pars convoluta
(presumably the pars recta) make the greater contri-
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x
Fig. 2. Data for fractional delivery of PAH to the late proximal
convoluted tubules and final urine from four micropuncture stud-
ies. The original presentation in study D [61] was in terms of
"late proximal" values. For studies A [62], B [63], and C [64],
we followed Hãberle's [63] convention of assigning sites at 47%
of tubular length and beyond to the late proximal category. The
dashed lines indicate the situations expected if PAH is 90% filter-
able [621; the point X on the ordinate indicates the intercept ex-
pected if 65% of PAH is filterable. If PAH is not completely fil-
terable, the apparent difference in the behavior of the pars con-
voluta and the pars recta of the proximal tubule in studies C and
D would diminish. It is, of course, assumed that the difference in
fractional delivery of PAH between the late proximal convoluted
tubule and the pelvic urine is the result of secretion in the pars
recta. The numbers of tubules punctured are indicated (N). The
bars (I) indicate SCM. For study D, PPAH was calculated from
the rate of PAH infusion and its renal clearance, assuming a
steady state.
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Table 3. Mean data from three free-flow micropuncture studies in rats with endogenous concentrations of plasma urate (Purate)'
Analytical method
Infusion rate
pi/min
Prate
pg ml
Fractional delivery
Early prox Late prox Distal Urine
Fluorimetric 50 6.3 0.53 0.43 0.40 0.32
HPLC-EC 15 6.5 0.78 0.53 0.36 0.34
6-'4C-Urate 20 — 0.77 0.68 0.63 0.55
The data, reading from the top, are from Refs. 38 and 42 and an as yet unpublished study by Roch-Ramel et al. HPLC-EC refers to
high performance liquid chromatography with electrochemical detection. The rate of infusion of 6-14C-urate (0,065 moles/min) was too
low to have a major effect on the concentration of urate in plasma (cf. [42]).
bution to net secretion. It may be pertinent that in
studies C and D the fractional excretion of PAH
was relatively low; it appears as if secretion may
have been saturated. It may be that the pars recta
has a greater tubular maximum reabsorptive capac-
ity (Tm) for PAH than does the pars convoluta, and
this, of course, would be apparent only when secre-
tion is saturated.
As indicated previously, a secretory flux for urate
occurs in the pars convoluta. Unfortunately, the
relative distribution of secretory activity for urate
between the two parts of the proximal tubule is not
known and, therefore, one cannot use this factor to
settle the question of whether or not PAH and urate
are secreted by the same mechanism. The best evi-
dence on this point comes from capillary micro-
injection studies. When urate and inulin are injected
into the capillary circulation, urate excretion pre-
cedes inulin excretion, evidence for secretion of
urate [60]. When pyrazinoate is included in the in-
jected solution, the precession of urate is nearly
abolished. PAH at comparable concentrations has
no effect.
There is a fairly large number of papers in which
the effects of various drugs on urate transport have
been studied in rats with aid of microtechniques;
most of these are cited in the chapter by Roch-Ra-
mel and Peters [3].
Microperfusion experiments in vivo reveal some
reabsorption of urate in the segments between the
proximal convoluted tubules and the distal tubules
[40, 59]. The fractional reabsorption of urate in this
part of the nephron is inversely related to flow rate
[59]. In the second free-flow micropuncture study
summarized in Table 3, the fractional delivery of
urate to the late proximal tubules exceeded frac-
tional delivery to the distal tubules significantly. It
may be pertinent that the rate of fluid infusion in
that study was the lowest of the group. In other ex-
periments (not shown), both volume expansion and
osmotic diuresis eliminated reabsorption between
the late proximal and distal tubules. In addition,
volume expansion, but not osmotic diuresis, inhib-
ited fractional reabsorption of urate in the proximal
convoluted tubules (Roch-Ramel et al, unpub-
lished).
There is virtually no urate reabsorption in the dis-
tal convoluted tubules [32, 40, 42]. Some free-flow
micropuncture experiments suggest that fractional
delivery of urate to the distal tubule is greater than
fractional excretion, others do not (for example, in
Table 3). There is one tubular microinjection study
that indicates the existence of a very small, satu-
rable reabsorptive process for urate in the collecting
system [90].
Drugs. It has long been known that drugs that in-
fluence urate excretion in man may have the same
action, an opposite action, or no action at all in ani-
mals. See, for example, the varied responses to
probenecid summarized in Table 4. All of the factors
that play a role are not known, l?ut two come to
mind immediately. First, many of the compounds
that influence urate excretion have dual actions;
they inhibit both secretion and reabsorption of urate
(for an example, see Ref. 12). In a particular spe-
cies, one or the other transport mechanism may be
more susceptible to inhibition. Second, if a drug
were equally effective in inhibiting secretion and
reabsorption, it would be expected that its net effect
would reflect the inhibition of the larger process, se-
cretion or reabsorption.
The material considered in the earlier parts of this
paper suggests additional important factors, some
of which may be considered in terms of a hypotheti-
cal drug. (The choice of a hypothetical compound is
dictated by the fact that we do not have sufficiently
detailed knowledge about any actual drug.) The
properties of this compound are: (1) it is largely
bound to serum albumin; (2) it is secreted by the
PAH-sensitive urate secretory mechanism, and
thus it is a competitive inhibitor of that mechanism;
(3) it is not secreted by the pyrazinoate-sensitive
urate secretory mechanism, and thus is not a com-
petitive inhibitor of that mechanism; (4) it is an in-
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Table 4. Change in urate excretion associated with administration of probenecid
Species Response Ref.
Monkey (Cebus)
Non-Dalmation dog
Dalmation coach hound
Rabbit
Rat
Pig
Snake
Increase
Small increase or no change
Decrease
Decrease
Increase or no change
Decrease
Decrease
[49]
[53, 91-94]
[53, 92, 93, 95, 96]
[58, 97—100]
[30, 85]
[65]
[66, 67]
Table 5. Properties of some uricosuric drugs and examples of
compounds with these properties
Properties and examples Ref.
1. Extensively bound to plasma proteins
a. Probenecid [101]
b. Sulfinpyrazone [23]
c. Ticrynafen [102]
d. Halofenate [103]
2. Probably secreted by PAH mechanism
a. Probenecid [8]
b. Halofenate [103]
c. Ticrynofen [102]
3. Probably do not cause extensive inhibition of
pyrazinoate-sensitive urate secretion at
uricosuric doses
a. Probenecid [8]
b. 2-Nitroprobenecid [24]
c. Mersalyl [83]
hibitor of urate reabsorption. These properties are
among those encountered among various uricosuric
drugs (see Table 5 for some examples). Consider
that the hypothetical drug is administered to a rab-
bit in which there is net urate secretion and that the
drug decreases urate excretion. The major site of
net urate reabsorption in the rabbit is the proximal
convoluted tubule [43], which has a relatively low
capacity to secrete PAH (and thus, the drug) [56].
As a consequence of this factor and of protein bind-
ing, the concentration of the drug in the fluid of the
proximal tubule may not be sufficient to inhibit sig-
nificantly the reabsorption of urate. (With at least
some drugs it is the concentration in tubular fluid
which determines inhibition of urate reabsorption
[8, 9, 11, 12, 24, 104—106].) Because this hypotheti-
cal drug is secreted by the PAH mechanism, which
in the rabbit is most active in the pars recta, which
also secretes urate in this species, it may well inhib-
it urate secretion by competition. In contrast, the
hypothetical drug may be uricosuric in Cebus. In
this animal, the drug would not compete with urate
for secretion because the two substances are se-
creted by separate mechanisms. Drug secretion is
prominent in the proximal convoluted tubule, which
is also the major site of urate reabsorption (Table 1);
thus, the drug can presumably reach the site of un-
cosuric action. It is possible, however, that in the
earliest part of the proximal tubule the concentra-
tion of the drug may not be sufficient to cause a seri-
ous impairment of urate reabsorption, and thus the
overall reabsorption of urate may be only partially
inhibited. This factor probably explains why dose-
response curves for some uricosuric drugs are not
"complete"; that is, the theoretical maximal effect
is not attainable. A mathematical analysis of these
factors has been presented by Fanelli and Weiner
[24].
The foregoing considerations indicate that a fairly
large number of factors will determine the direction
and extent of response to drugs that influence urate
excretion. Among these factors are: (1) dose; (2) po-
tency with respect to inhibition of urate reabsorp-
tion; (3) binding of drug to plasma proteins; (4) ex-
tent of drug secretion; (5) site of drug secretion; (6)
site of urate reabsorption; (7) nature of the urate se-
cretory mechanism (the PAH mechanism or anoth-
er); (8) affinity of the drug for the PAH mechanism;
(9) the ability of the compound to inhibit the pyrazi-
noate-sensitive mechanism for urate secretion; (10)
the direction of net urate transport in the animal
studied.
There are, in addition, several complicating fac-
tors. In some settings, a drug may have the ability
to inhibit both PAH and urate secretion even when
these substances are secreted by separate mecha-
nisms; for example, probenecid in snakes (see
above). Second, there is a body of evidence sug-
gesting that not all anionic drugs are secreted by the
PAH mechanism [77, 107]. Third, there are ex-
amples of foreign organic anions that are secreted in
some species but not in others [108, 109]. Fourth, in
addition to the fact that peak PAH secretion may
occur in different portions of the proximal tubule, it
is also possible that there is more than a single se-
cretory mechanism for PAH [11]. Finally, there is
the suggestion in the rat that there may be more
than one reabsorptive mechanism for urate in the
proximal tubule [89].
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